Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1774 | Hydroxychloroquin with Azithromycin Wiki | 0.50 |
| drug4582 | miniprobe Alveoflex Wiki | 0.50 |
| drug2396 | Mindfulness training (MT) Connect Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016638 | Critical Illness NIH | 0.12 |
| D007239 | Infection NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be rapidly available when there are sufficient numbers of people who have recovered and can donate high titer neutralizing immunoglobulin-containing plasma. Hypothesis: Collecting and administering convalescent plasma requires a level of logistical coordination that is not available in all centers. Objective: To establish feasibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.
Description: Feasibility will be measured by (number of donors from whom convalescent plasma is harvested/number of interested donors) and number of patients who receive convalescent plasma at day 28.
Measure: Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients Time: 28 days after plasma administrationDescription: Levels of respiratory support will be graded (e.g. room air, high flow oxygen, intubation) to determine the change in type of respiratory support at 28 days.
Measure: Type of respiratory support Time: 28 days after plasma administrationDescription: This will be a continuous outcome defined by the amount of time between plasma administration and cardiac arrest.
Measure: Cardiac arrest Time: 28 days after plasma administrationDescription: This will be a continuous outcome defined by the amount of time between plasma administration and transfer to ICU.
Measure: Transfer to ICU Time: 28 daysDescription: This will be a binary outcome defined by the amount of time between plasma administration and mortality in the ICU.
Measure: ICU mortality Time: 28 daysDescription: This will be a continuous outcome defined by the amount of time between plasma administration and discharge from ICU. This will be treated as a time-to-event.
Measure: ICU length of stay Time: 28 daysDescription: This will be a binary outcome defined by the amount of time between plasma administration and in-hospital mortality.
Measure: Hospital mortality Time: 28 daysDescription: This will be a continuous outcome defined by the amount of time between plasma administration and discharge from hospital.
Measure: Hospital length of stay Time: 28 daysDescription: This will be a continuous outcome defined by the amount of time between plasma administration and the transition from mechanical ventilation to non-invasive respiratory support.
Measure: Ventilator-free days Time: 28 daysDescription: 28-Day Overall Survival is defined as the status of the patient at the end of 28 days, beginning from the time of plasma administration.
Measure: Overall survival (28-day mortality) Time: 28 daysWhy is the research needed? The pandemic known as COVID-19 is now spreading across the world with currently (April 10, 2020) more than 1 115 530 active cases and 96 791 deaths. In most affected countries the current goal is to 'flatten the curve' of the epidemic since there is no health care system that is able to treat an extremely high volume of patients all at once. There is a need for immediately applicable treatments for the patients at highest risk, which gains time until targeted therapies become available. A key feature in the pathomechanism of the disease is that the virus elicits an immunological over-reaction in the human body termed 'cytokine storm'. In susceptible patients this hyper-inflammation itself is a significant burden and may even inhibit the body to generate antibodies against the virus in adequate quantities. Therefore, identifying the subset of patients with excess cytokine response and supplementing them with convalescent plasma from recovered donors may be a life-saving treatment option. What is our study about? In light of recent promising data on plasma therapy in the treatment of COVID-19 and other viral epidemics, there is a need for better understanding the cytokine response to the virus in order to better characterize the target population for convalescent plasma therapy. Our hypothesis is that convalescent plasma transfusion from healthy donors who recovered from SARS CoV-2 is able to reduce the cytokine storm in addition to replenish the patient's own antibodies in the acutely infected phase of the disease. A plasmapheresis donation of 400ml will be performed in subjects who recovered from COVID-19 and who are otherwise eligible for plasma donation. The sample will be tested for anti-SARS CoV-2 neutralizing antibody titers and those that reach the level of 1:320 will be processed for transfusion at the Hungarian National Transfusion Service. Recipients will be COVID-19 patients requiring hospitalization regardless of the severity of the disease or other co-morbidities. A blood-type matched transfusion of 200 ml convalescent plasma will be infused in a single sitting through an iv. infusion of 4 hours. Recipients will be followed up at days 1, 3,7,12, 17, 28 for clinical symptoms, antibody levels and cytokine response.
Description: Copies of COVID-19 per ml
Measure: Changing of viral load of SARS-CoV2 Time: Day 1,3, 7, 12Description: Immunoglobulin G COVID-19 antibodies Immunglobulin G antibody titer
Measure: Changes in immunglobulin G COVID-19 antibody titer Time: 12 daysDescription: Proportion of patients with Intensive Care Unit Admission requirement
Measure: Intensive Care Unit Admission Time: Day 7,12,28Description: Days of Hospitalization
Measure: Length of hospital stay Time: Day 7, 12, 28Description: Days with mechanical ventilation
Measure: Duration of mechanical ventilation Time: Day 7, 12, 28Description: Clinical status assessed according to the World Health Organization guideline
Measure: Clinical Status Time: Day 7, 12, 28Description: Proportion of death patients at days
Measure: Mortality Time: Day 7, 12, 28This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
Description: Overall mortality within 60 days
Measure: Overall Mortality within 60 days Time: sixty days from infusion of plasmaDescription: length of admission for COVID
Measure: Length of ICU stay during current admission for COVID Time: Length of admission for COVID through study follow-up period, an average of 60 daysAdministration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
Description: The total number of days patients required respiratory support.
Measure: Duration of oxygenation and ventilation support Time: 28 days after transfusion or until hospital discharge (whichever comes first)Description: Total number of days patients were admitted to the hospital.
Measure: Hospital length of stay (LOS) Time: 28 days after transfusion or until hospital discharge (whichever comes first)Description: Total number of subjects to be admitted to the ICU after the convalescent plasma transfusion.
Measure: ICU admission Time: 28 days after transfusion or until hospital discharge (whichever comes first)Description: Days without oxygenation support after receiving convalescent plasma
Measure: Ventilator free days Time: 28 days after transfusion or until hospital discharge (whichever comes first)Description: Cumulation incidence of serious adverse events during the study protocol
Measure: Incidence of serious adverse events Time: 28 days after transfusion or until hospital discharge (whichever comes first)Description: Type of supplemental oxygen support (e.g. nasal canula, high flow nasal canula, noninvasive ventilation, intubation and invasive mechanical ventilation, rescue ventilation)
Measure: Type of respiratory support Time: 28 days after transfusion or until hospital discharge (whichever comes first)Description: Number of participants with different clinical outcomes including death, critical illness and recovery
Measure: Number of participants with different clinical outcomes including death, critical illness and recovery Time: 28 days after transfusion or until hospital discharge (whichever comes first)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports